Literature DB >> 11244564

Hepatitis B viral X protein overcomes inhibition of E2F1 activity by pRb on the human Rb gene promoter.

B H Choi1, M Choi, H Y Jeon, H M Rho.   

Abstract

Hepatitis B virus X (HBx) protein is known as an oncogenic transactivator, E2F1 as a positive regulator of the cell cycle, and pRb as a tumor suppressor. Here, we investigated the functional interactions of these proteins on the human Rb promoter. Interestingly, HBx transactivated the Rb promoter cooperatively with E2F1 in HepG2 cells but not in HeLa cells, in which the functions of p53 and pRb are inactive. Combinatorial cotransfection analyses in HepG2 cells showed that HBx overcame the inhibition of E2F1 activity by pRb but not that by p53. Domain analysis showed that aa 47-70 and aa 117-133 of HBx are important for this effect. These results suggest that HBx could inhibit the pRb tumor suppressor and increase E2F1 activity. Our data support the oncogenic potential of HBx, which may cause HBV-infected cells to grow continuously in the development of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244564     DOI: 10.1089/104454901750070274

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  16 in total

Review 1.  Viral manipulation of DNA repair and cell cycle checkpoints.

Authors:  Mira S Chaurushiya; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2009-05-26

Review 2.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein.

Authors:  Cheryl Chan; Yu Wang; Pierce K H Chow; Alexander Y F Chung; London L P J Ooi; Caroline G Lee
Journal:  Mol Cell Biol       Date:  2012-11-12       Impact factor: 4.272

4.  A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma.

Authors:  Yingyi Liu; Ye Yao; Bo Liao; Hao Zhang; Zhangshuo Yang; Peng Xia; Xiang Jiang; Weijie Ma; Xiaoling Wu; Chengjie Mei; Ganggang Wang; Meng Gao; Kequan Xu; Xiangdong GongYe; Zhixiang Cheng; Ping Jiang; Xi Chen; Yufeng Yuan
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

5.  Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells.

Authors:  Lian Yang; Jun He; Libo Chen; Guobin Wang
Journal:  Med Oncol       Date:  2008-12-13       Impact factor: 3.064

6.  Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma.

Authors:  Jack Hutcheson; Ryan J Bourgo; Uthra Balaji; Adam Ertel; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Hepatology       Date:  2014-08-28       Impact factor: 17.425

7.  Hepatitis C virus NS5B protein delays s phase progression in human hepatocyte-derived cells by relocalizing cyclin-dependent kinase 2-interacting protein (CINP).

Authors:  Yaohui Wang; Yuchan Wang; Yan Xu; Wenyan Tong; Tingting Pan; Jianhua Li; Shuhui Sun; Junjie Shao; Huanping Ding; Tetsuya Toyoda; Zhenghong Yuan
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

Review 8.  HBV induced HCC: major risk factors from genetic to molecular level.

Authors:  Ambreen Ayub; Usman Ali Ashfaq; Asma Haque
Journal:  Biomed Res Int       Date:  2013-08-07       Impact factor: 3.411

9.  Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest.

Authors:  Sharon Sheahan; Christopher O Bellamy; Donald R Dunbar; David J Harrison; Sandrine Prost
Journal:  BMC Cancer       Date:  2007-11-19       Impact factor: 4.430

10.  TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p53, p21Cip1 or Rb status.

Authors:  Sharon Sheahan; Christopher O Bellamy; Stephen N Harland; David J Harrison; Sandrine Prost
Journal:  BMC Cancer       Date:  2008-07-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.